Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>The minerals exploration and development Company reports that its proposed joint venture partner, GreenTech Metals Limited, has announced that the Phase 1 drill programme will be accelerated with the addition of a second drill rig at the Munni Munni Platinum-PalladiumCopper-Nickel Project.</li>
<li>GreenTech and Alien are progressing the final administrative processes to enable conclusion of the transaction, and a further announcement will be made in due course.</li>
<li>The developer of next-generation synthetic binders for the life sciences industry announced £190k of new fee-for-service orders and £80k of cash licensing receipts, demonstrating sustained commercial momentum and the commencement of high-margin, recurring revenues from its Optimer platform.</li>
</ul>


The minerals exploration and development Company reports that its proposed joint venture partner, GreenTech Metals Limited, has announced that the Phase 1 drill programme will be accelerated with the addition of a second drill rig at the Munni Munni Platinum-PalladiumCopper-Nickel Project.
GreenTech and Alien are progressing the final administrative processes to enable conclusion of the transaction, and a further announcement will be made in due course.
The developer of next-generation synthetic binders for the life sciences industry announced £190k of new fee-for-service orders and £80k of cash licensing receipts, demonstrating sustained commercial momentum and the commencement of high-margin, recurring revenues from its Optimer platform.


Strategic Minerals PLC - Hybridan Small Cap Feast: 29 January 2026

<ul>
<li>Abingdon Health 6.25p £11.71m (ABDX.L) The international developer, manufacturer and regulatory services provider for rapid diagnostic tests and medtech announces that, further to its announcement yesterday, it has completed and closed the placing to raise gross proceeds of £3.3m.</li>
<li>As part of the Placing, Chris Hand, Executive Chairman of the Company, has agreed to subscribe for £30k.</li>
<li>In addition to the Placing, the Company is providing existing eligible shareholders with the opportunity to subscribe for Retail Offer Shares at the Placing Price, to raise up to £200k. </li>
</ul>


Abingdon Health 6.25p £11.71m (ABDX.L) The international developer, manufacturer and regulatory services provider for rapid diagnostic tests and medtech announces that, further to its announcement yesterday, it has completed and closed the placing to raise gross proceeds of £3.3m.
As part of the Placing, Chris Hand, Executive Chairman of the Company, has agreed to subscribe for £30k.
In addition to the Placing, the Company is providing existing eligible shareholders with the opportunity to subscribe for Retail Offer Shares at the Placing Price, to raise up to £200k. 


Sosandar PLC - Hybridan Small Cap Feast: 14/10/2025

<ul>
<li>1Spatial Holdings 53.0p £60.87m (SPA.L) The global Location Master Data Management software and solutions provider reports Interims to July.</li>
<li>Revenue increased 9% to £17.7m with a 50% increase in SaaS Term licenses to £0.8m and ARR grew 11.9% to £19.1m.</li>
<li>The is EBITDA improved to £2.1m from £2m, while the LBT increased to £0.3m from £0.2m. </li>
</ul>


1Spatial Holdings 53.0p £60.87m (SPA.L) The global Location Master Data Management software and solutions provider reports Interims to July.
Revenue increased 9% to £17.7m with a 50% increase in SaaS Term licenses to £0.8m and ARR grew 11.9% to £19.1m.
The is EBITDA improved to £2.1m from £2m, while the LBT increased to £0.3m from £0.2m. 


<ul>
<li>Angle 2.20p £8.87m (AGL.L) The precision intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development, and clinical oncology revises its business strategy.</li>
<li>The Chairman, Dr Jan Groen, has moved into an executive role to lead the Company as it focuses on tight cost control, accelerated commercial progress, and a clear plan towards becoming a sustainable business.</li>
<li>As part of its revised strategy, the Company proposes to change its name to Ce1LBxHealth plc to reflects the sharpened focus on the provision of high-value CTC-based precision diagnostic testing. </li>
</ul>


Angle 2.20p £8.87m (AGL.L) The precision intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development, and clinical oncology revises its business strategy.
The Chairman, Dr Jan Groen, has moved into an executive role to lead the Company as it focuses on tight cost control, accelerated commercial progress, and a clear plan towards becoming a sustainable business.
As part of its revised strategy, the Company proposes to change its name to Ce1LBxHealth plc to reflects the sharpened focus on the provision of high-value CTC-based precision diagnostic testing. 


Xeros Technology Group Plc - Hybridan Small Cap Feast: 08/10/2025

<ul>
<li>1Spatial 44.5p £56.76m (SPA.L) The global Location Master Data Management software and solutions Company announces finals to January 2025.</li>
<li>There is a 3% increase in revenue to £33.4m of which 62% is recurring up from 56%, last year.</li>
<li>The operating profit decreased to £0.9m from £1.4m reflecting higher costs with a net debt of £1m compared to net cash of £1.1m. </li>
</ul>


1Spatial 44.5p £56.76m (SPA.L) The global Location Master Data Management software and solutions Company announces finals to January 2025.
There is a 3% increase in revenue to £33.4m of which 62% is recurring up from 56%, last year.
The operating profit decreased to £0.9m from £1.4m reflecting higher costs with a net debt of £1m compared to net cash of £1.1m. 


United Kingdom

Aptamer Group Plc is a biotechnology company that provides Optimer binders for use in research, diagnostics, and therapeutics. The company utilizes its proprietary Optimer technology to offer custom development services for oligonucleotide-based binders, aiming to deliver transformational solutions across the life sciences industry. Aptamer Group was founded in 2008 and is headquartered in York, United Kingdom.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Aptamer Group (APTA LN)

Strategic Minerals PLC - Hybridan Small Cap Feast: 29 January 2026

GreenTech and Alien are progressing the final administrative processes to enable conclusion of the transaction, and a further announcement will be...

Hybridan

Sosandar PLC - Hybridan Small Cap Feast: 14/10/2025

In addition to the Placing, the Company is providing existing eligible shareholders with the opportunity to subscribe for Retail Offer Shares at...

Hybridan

Hybridan Small Cap Feast: 13/10/2025

1Spatial Holdings 53.0p £60.87m (SPA.L) The global Location Master Data Management software and solutions provider reports Interims to July.

Hybridan

Xeros Technology Group Plc - Hybridan Small Cap Feast: 08/10/2025

The precision intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development, and...

Hybridan

Hybridan Small Cap Feast: 07/05/2025

1Spatial 44.5p £56.76m (SPA.L) The global Location Master Data Management software and solutions Company announces finals to January 2025.

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)